Marco Iansiti

June 24, 2022

Marco is the David Sarnoff Professor of Business Administration at Harvard Business School, where he heads the Technology and Operations Management Unit and the Digital Initiative. He co-founded Keystone Strategy in 2003 and serves as the Chairman of the Board of Directors.

An expert on digital innovation and transformation, Marco has a special focus on strategy, business models, and new product development in high technology industries. He is the author or coauthor of more than 100 publications. His second book, The Keystone Advantage: What the New Dynamics of Business Ecosystems Mean for Strategy, Innovation, and Sustainability was selected as one of the 10 best business books of the year in 2004 by Strategy and Business. Marco advises a variety of Fortune 500 companies with a focus on digital strategies and transformation. He has been a faculty member at Harvard Business School since 1989.

Securing the Future of the U.S. Biopharmaceutical Industry: The Most-Favored-Nation Paradox

February 5, 2026

By Sujai Shivakumar and Anne Pritchett The Trump administration is pursuing lowering prescription drug costs primarily to end what it describes as “global freeloading” and to ensure U.S. patients pay prices comparable to those in other developed nations. The administration argues that while the United States represents less than 5 percent

Universities, Patents, and the Future of U.S. Competitiveness

December 15, 2025

By Shruti Sharma and Chris Borges Universities are among the most powerful engines of U.S. innovation, transforming federal research investments into scientific discoveries that underpin economic growth, technological leadership, and national security. Current law, via the Bayh-Dole Act, allows universities to patent inventions and license them to private companies, with royalties

How Counterfeit Drugs Threaten U.S. Health and Innovation

November 19, 2025

By Anne Pritchett According to the Department of Homeland Security, counterfeit drugs “threaten national security and public safety directly when introduced into government and critical infrastructure supply chains, and indirectly if used to generate revenue for transnational criminal organizations.” Furthermore, counterfeit drugs harm pharmaceutical innovation by eroding profitability and investor